These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31578814)

  • 1. Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a).
    Pasternack R; Büchold C; Jähnig R; Pelzer C; Sommer M; Heil A; Florian P; Nowak G; Gerlach U; Hils M
    J Thromb Haemost; 2020 Jan; 18(1):191-200. PubMed ID: 31578814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII.
    Rijken DC; Abdul S; Malfliet JJ; Leebeek FW; Uitte de Willige S
    J Thromb Haemost; 2016 Jul; 14(7):1453-61. PubMed ID: 27148673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
    Beckman JD; Holle LA; Wolberg AS
    J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of factor XIII in ischemic stroke: a key molecule promoting thrombus stabilization and resistance to lysis.
    Marta-Enguita J; Navarro-Oviedo M; Machado FJDM; Bermejo R; Aymerich N; Herrera M; Zandio B; Pagola J; Juega J; Marta-Moreno J; Rodriguez JA; Páramo JA; Roncal C; Muñoz R; Orbe J
    J Thromb Haemost; 2024 Apr; 22(4):1080-1093. PubMed ID: 38160727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking.
    Byrnes JR; Duval C; Wang Y; Hansen CE; Ahn B; Mooberry MJ; Clark MA; Johnsen JM; Lord ST; Lam WA; Meijers JC; Ni H; Ariëns RA; Wolberg AS
    Blood; 2015 Oct; 126(16):1940-8. PubMed ID: 26324704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of blood coagulation factor XIII.
    Schmitz T; Bäuml CA; Imhof D
    Anal Biochem; 2020 Sep; 605():113708. PubMed ID: 32335064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor XIII and Fibrin Clot Properties in Acute Venous Thromboembolism.
    Ząbczyk M; Natorska J; Undas A
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Methods for the determination of factor XIII/XIIIa].
    Wilmer M; Schröder V; Kohler HP
    Hamostaseologie; 2002 Feb; 22(1):32-42. PubMed ID: 12193983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor XIII and venous thromboembolism.
    Bereczky Z; Muszbek L
    Semin Thromb Hemost; 2011 Apr; 37(3):305-14. PubMed ID: 21455864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis.
    Hethershaw EL; Cilia La Corte AL; Duval C; Ali M; Grant PJ; Ariëns RA; Philippou H
    J Thromb Haemost; 2014 Feb; 12(2):197-205. PubMed ID: 24261582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening cleavage of Factor XIII V34X Activation Peptides by thrombin mutants: A strategy for controlling fibrin architecture.
    Jadhav MA; Goldsberry WN; Zink SE; Lamb KN; Simmons KE; Riposo CM; Anokhin BA; Maurer MC
    Biochim Biophys Acta Proteins Proteom; 2017 Oct; 1865(10):1246-1254. PubMed ID: 28687225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protransglutaminase (factor XIII) mediated crosslinking of fibrinogen and fibrin.
    Siebenlist KR; Meh DA; Mosesson MW
    Thromb Haemost; 2001 Nov; 86(5):1221-8. PubMed ID: 11816711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-Based Design of FXIIIa-Blockers: Addressing a Transient Hydrophobic Pocket in the Active Site of FXIIIa.
    Stieler M; Büchold C; Schmitt M; Heine A; Hils M; Pasternack R; Klebe G
    ChemMedChem; 2020 May; 15(10):900-905. PubMed ID: 32181986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of PentaLyte and Voluven hemodilution on plasma coagulation kinetics in the rabbit: role of thrombin-fibrinogen and factor XIII-fibrin polymer interactions.
    Nielsen VG
    Acta Anaesthesiol Scand; 2005 Oct; 49(9):1263-71. PubMed ID: 16146462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor XIII, clot structure, thrombosis.
    Bagoly Z; Koncz Z; Hársfalvi J; Muszbek L
    Thromb Res; 2012 Mar; 129(3):382-7. PubMed ID: 22197181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FXIII polymorphisms, fibrin clot structure and thrombotic risk.
    Kobbervig C; Williams E
    Biophys Chem; 2004 Dec; 112(2-3):223-8. PubMed ID: 15572253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of activated factor XIII by polymorphonuclear granulocyte proteases within fibrin clot.
    Bagoly Z; Haramura G; Muszbek L
    Thromb Haemost; 2007 Aug; 98(2):359-67. PubMed ID: 17721618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of factor XIII activation by an anti-peptide monoclonal antibody.
    Lukacova D; Matsueda GR; Haber E; Reed GL
    Biochemistry; 1991 Oct; 30(42):10164-70. PubMed ID: 1681898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Hextend hemodilution on plasma coagulation kinetics in the rabbit: role of factor XIII-mediated fibrin polymer crosslinking.
    Nielsen VG
    J Surg Res; 2006 May; 132(1):17-22. PubMed ID: 16154147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hierarchies in the binding of human factor XIII, factor XIIIa, and endothelial cell transglutaminase to human plasma fibrinogen, fibrin, and fibronectin.
    Achyuthan KE; Rowland TC; Birckbichler PJ; Lee KN; Bishop PD; Achyuthan AM
    Mol Cell Biochem; 1996 Sep; 162(1):43-9. PubMed ID: 8905624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.